Curadev, Roche deal

Curadev and Roche partnered to develop inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase ( TDO2; TDO) to treat cancer. The deal gives Roche exclusive, worldwide rights to develop and commercialize Curadev’s lead compound, CRD1152, which is a small molecule dual IDO1/TDO inhibitor. Curadev will receive $25 million up front and is eligible for up to $530 million in milestones, plus escalating royalties up to double digits. Roche declined to say when it plans to start a clinical trial of CRD1152. ...